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Abstract
Background: After the re-introduction of ImmunoCAP® 
ISAC sIgE 112 on the market, we undertook a study to eval-
uate the performance of this multiplex-based immunoas-
say for IgE measurements to allergen components.
Methods: The study was carried out at 22 European 
and one South African site. Microarrays from different 
batches, eight specific IgE (sIgE) positive, three sIgE nega-
tive serum samples and a calibration sample were sent to 
participating laboratories where assays were performed 
according to the manufacturer’s instructions.
Results: For both the negative and positive samples 
results were consistent between sites, with a very low fre-
quency of false positive results (0.014%). A similar pattern 
of results for each of the samples was observed across 
the 23 sites. Homogeneity analysis of all measurements 
for each sample were well clustered, indicating good 
reproducibility; unsupervised hierarchical clustering and 
classification via random forests, showed clustering of 
identical samples independent of the assay site. Analy-
sis of raw continuous data confirmed the good accuracy 
across the study sites; averaged standardized, site-specific 
ISU-E values fell close to the center of the distribution of 
measurements from all sites. After outlier filtering, vari-
ability across the whole study was estimated at 25.5%, 
with values of 22%, 27.1% and 22.4% for the ‘Low’, ‘Mod-
erate to High’ and ‘Very High’ concentration categories, 
respectively.
Conclusions: The study shows a robust performance of 
the ImmunoCAP® ISAC 112 immunoassay at different sites. 
Essentially the same results were obtained irrespective 
of assay site, laboratory-specific conditions and instru-
ments, operator, or the use of microarrays from different 
batches.
Keywords: allergen component; component resolved 
diagnostics; ImmunoCAP® ISAC 112; microarray; molecu-
lar allergology; specific IgE.
Introduction
The use of allergen extracts to determine sensitizations 
underlying allergic symptoms is often confounded by 
cross-reacting allergens and poly-sensitizations [1–3]. 
Measuring specific immunoglobulin E (sIgE) antibodies 
against individual components (allergen molecules) can 
separate genuine (primary) and cross-reactive (second-
ary) sensitizations, thus providing valuable information 
on the individual IgE-repertoire and improving diagnosis 
of allergic diseases [2–6].
The ImmunoCAP® ISAC (Immuno Solid-phase Aller-
gen Chip) sIgE 112 (ISAC 112) is a microarray-based immu-
noassay that enables simultaneous measurement of 
specific antibodies against an array of 112 recombinant 
or purified native allergen components derived from over 
50 allergen sources [7–9]. Fluorescently labeled anti-IgE 
antibodies detect specific IgE from a serum or plasma test 
sample that binds to the immobilized allergen compo-
nents. Fluorescence intensity is measured by a microarray 
scanner, converted to arbitrary concentration units, and is 
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then displayed both in arbitrary units ISAC Standardized 
Units for IgE (ISU-E), being internally cross-calibrated to 
ImmunoCAP singleplex kUA/l, and as semi-quantitative 
values (classes). The technical and clinical performances 
of the ISAC 112 have been validated in several studies that 
– depending on the allergen component – report compa-
rable results to quantitative singleplex ImmunoCAP aller-
gen component tests [3, 10–19].
After customers having experienced problems with 
increasing background signals, the product was retracted 
by the manufacturer, and re-introduced after improvements 
in the production process had been made. The relaunched 
ImmunoCAP ISAC 112, is slightly modified with respect to 
allergen lay-out, and therefore requires an adapted soft-
ware tool. The array is unchanged with respect to allergen 
composition – the only change is that the purity of the 
native Timothy allergen Phl p 4 has been improved.
The ISAC 112 platform provides a minimally invasive, 
rapid and efficient means of testing IgE sensitizations to 
a broad panel of allergen components [3], and has been 
used as an aid in the diagnosis and risk assessment of 
allergic patients [20–25], to predict allergic symptoms as 
well as for prescription and monitoring of immunother-
apy [26–30], sensitization profiling [31–34], and for the 
study of allergic diseases [16, 35–37].
The objective of this study was to evaluate the per-
formance of the ISAC 112 microarray in a real life setting 
using identical assays performed by different operators in 
multiple sites worldwide.
Materials and methods
Study design
The study was designed to cover as many relevant parameters as 
possible, including number of laboratories, geographic areas and 
batches of the array which would guarantee the largest possible 
between assay variation. The number of positive and negative sera 
and the assay design were governed by creating enough positive and 
negative results for every component on the chip in order to be able 
to perform useful statistical analysis.
Twenty-three sites, 22 in Europe and one in South Africa, par-
ticipated in the study (see Supplemental Data, Table 1). Microarrays, 
sourced randomly from ten different batches, and aliquots of eight 
sIgE positive serum samples (Pos 1–8), three sera with sIgE < 0.1 kUA/l 
(Neg 1–3) as well as the calibration sample were sent out to partici-
pating sites within the same week and the assays were performed 
according to the manufacturer’s instructions during the following 4 
weeks.
The eight positive samples contained sIgE to 110 of the 112 aller-
gen components present on the microarray (Table 1) at different lev-
els covering the whole measuring range of the assay (0.3–100 ISU-E).
Table 1: Number of IgE-reactive components for each of the positive 
serum samples and numbers of sample-component interactions per 
semi-quantitative concentration category.
Serum 
sample
  Number of 
IgE-reactive 
components 
(n)
 
 
Number of IgE responses per semi-
quantitative category
‘Low’ (0.3–3 
ISU-E)
  ‘Moderate to 
High’ (3–15 
ISU-E)
  ‘Very High’ 
(> 15 ISU-E)
Pos 1   13   5   5   3
Pos 2   76   24   38   14
Pos 3   59   26   24   9
Pos 4   46   18   18   10
Pos 5   88   29   42   17
Pos 6   95   23   20   52
Pos 7   78   20   24   34
Pos 8   79   29   34   16
ISAC 112 method
ImmunoCAP ISAC 112 (Phadia AB, Uppsala, Sweden) was run accord-
ing to the instructions of the manufacturer. Briefly, 30 μL of serum 
samples was added to each microarray and incubated at room tem-
perature for 120 min. After washing, 30 μL fluorescence-labeled anti-
human IgE antibodies were added. Following incubation for 30 min, 
unbound labeled antibodies were removed by washing and fluores-
cence was measured in an appropriate microarray scanner available 
in the respective laboratory. Fluorescence measurements from anti-
IgE antibodies were compared with a calibration curve and expressed 
as arbitrary ISU-E. In addition to reporting continuous ISU-E values, 
test results were analyzed with Phadia Microarray Image Analysis 
(MIA) Software and ISU-E measurements were assigned to one of four 
categories on a semi-quantitative ordinal scale ranging from ‘Unde-
tectable or Very Low’ (0–0.3 ISU-E), to ‘Low’ (0.3–3 ISU-E), ‘Moderate 
to High’ (3–15 ISU-E), and ‘Very High’ (> 15 ISU-E).
The assay was calibrated using a sample containing known 
amounts of humanized antibodies with several different allergen 
specificities. The calibration sample used contains 14 chimeric IgE 
antibodies specific for 14 different allergen components, and is 
mixed in ratios to obtain concentrations covering the entire measur-
ing range. The concentration of each individual chimeric antibody is 
determined by singleplex ImmunoCAP assays for the corresponding 
allergen component (ImmunoCAP®, Phadia AB, Uppsala, Sweden). 
The calibration sample is thus cross-calibrated against singleplex 
specific IgE, which in turn is linked by heterologous interpolation to 
the World Health Organization (WHO) International Reference Rea-
gent 75/502 for total serum IgE.
Data analysis
Homogeneity analysis was carried out on discrete semi-quantitative 
data from the eight positive serum samples as described by De Leeuw 
and Mair [38]. To evaluate if measurements from identical samples 
assayed at different sites clustered into identical groups, we assessed 
clustering of the entire dataset into sets of samples. Hierarchical 
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clustering and clustering using random forests was performed using 
positive and negative serum samples as described [39].
For quantitative analyses, raw continuous ISU-E measurements 
were used after outlier filtering to obtain an aggregate score of accu-
racy across sites. Outliers were defined using a local outlier factor 
algorithm with a fixed number of neighbors (n = 8); the outlier factor 
was set so that < 5% of the total data was discarded, thus reflecting 
outlying results in the quality control practice [40].
Standardized ISU-E values were calculated from sample-compo-
nent assay result combinations with values  ≥  0.3 ISU-E from at least 
22 of the 23 sites. In total, 444 of 896 possible combinations met these 
criteria. For each of the 444 sample-component combinations, stand-
ardized ISU-E values were calculated by dividing the site-specific val-
ues by the mean value from all sites. Site-specific aggregate ISU-E 
means were calculated as the mean of all 444 standardized ISU-E 
values from that site.
Site-specific coefficients of variation (CV) were calculated using 
the quantitative ISU-E values obtained from the 444 sample-compo-
nent combinations. The CV across all sites (CVTotal) was estimated as 
the median of all combination-based estimates of variation from the 
study sites.
User questionnaire
A questionnaire including three questions on ease of handling was 
sent to each site; questions and answer options were:
1. In your opinion, was performing of the updated ISAC 112 assay; 
(Easy, Neither easy nor difficult, Difficult)
2. Did you receive an approved calibration curve the first time you 
ran the quality control assay? (Yes or no)
3. How was the usability of the updated MIA software, version 
1.2.4? (Easy, Neither easy nor difficult, Difficult).
Results
Semi-quantitative analysis
Discrete, categorized, IgE measurements from unfiltered 
data are shown by study site and by sample in Figure 1. 
We observed a similar pattern of results for each of the 11 
samples across the 23 sites (Figure 1A). Categorized values 
for the three negative samples and one positive sample are 
presented in Figure 1B, showing that ISU categories for 
negative and positive samples were consistent between 
the different sites. Of 7728 measurements of the three neg-
ative samples (3 samples and 112 allergen components at 
23 sites), only one yielded a signal slightly above 0.3 ISU, 
corresponding to a low frequency (0.014%) of false posi-
tive results.
A homogeneity analysis of semi-quantitative meas-
urements was performed to visualize the degree of dis-
persion between the different sites and within the assay 
runs. Figure  2 shows the projection for the eight posi-
tive samples at each of the 23 sites, where the number 
of dimensions have been reduced from 110, based on the 
number of IgE-reacting allergens components for each 
sample, down to two, allowing for easy visualization. 
This projection illustrates the degree of similarity/dispar-
ity between the samples, since samples with similar prop-
erties, i.e. sensitization pattern, cluster in each other’s 
vicinity. Samples having clusters with low levels of dis-
persion demonstrate a less reactive sensitization pattern, 
e.g. positive sample 1 with 13 IgE-reacting allergen com-
ponents displayed the lowest degree of within-sample 
dispersion, while other samples with 46–95 IgE-reacting 
allergen components demonstrated a higher degree of 
dispersion. Although the degree of dispersion differed 
slightly between the samples, the 23 measurements for 
each sample were well clustered, indicating good repro-
ducibility of the assay.
Using unsupervised hierarchical clustering as well as 
classification via random forests, we observed clustering 
of samples with the same identity regardless of the assay 
site. The visual impression of correct classification was 
confirmed by the classification error of zero (Supplemen-
tal Data, Figures 1 and 2).
Quantitative analysis
Of 896 possible combinations of samples and allergen 
components (8 positive samples and 112 allergen compo-
nents) around half (n = 444) gave measured values  ≥  0.3 
ISU-E at > 95% of the sites. Figure 3 shows the distribution 
of standardized ISU-E values of the 444 measured values 
from all 23 sites (n = 10,212 in total), and aggregate means 
of standardized ISU-E values for each site. Precision of 
the assay at each site is indicated by the proximity of the 
aggregate mean value to the center of the distribution. 
Aggregate mean values fell close to the center of the distri-
bution with a similar number on either side; only one site 
had a value outside the range 0.5–1.5.
Total variability
Median between-site variation in ISU-E values for the 444 
sample-component combinations with values  ≥  0.3 ISU at 
> 95% of the sites was calculated to estimate total preci-
sion. After filtering outliers, which correspond to < 5% of 
total measurements, CVtotal was estimated at 25.5%. Includ-
ing the outlying values led to an estimate of approximately 
29.9%. Estimates of variability for each of the positive ISU 
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Figure 1: Heat map representation of semi-quantitative data by assay site and sample.
(A) Sites are separated by the solid vertical lines. At each site, samples from left to right are: 1–3 negative, 4–12 positive, and the refer-
ence sample; the 112 components are distributed on the vertical axis. (B) Samples are separated by the solid vertical line. From left to right 
these are three negative and one positive sample. The assay sites are distributed on the horizontal axis between the vertical lines for each 
sample. The 112 components are distributed on the vertical axis.
Figure 2: Projection of measurements based on all 112 components onto a 2-dimensional plane for eight positive samples at each of the 23 sites.
Dispersion within each cluster is a function of the sample reactivity.
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categories for filtered data were: ‘Low’ 22%, ‘Moderate to 
High’ 27.1%, and ‘Very High’ 22.4%.
User questionnaire
Fifteen of the users found the assay easy to perform and 
14 found the evaluation process using the software MIA 
easy. Five users answered that the performance of the 
assay and the evaluation process was neither easy nor 
difficult, while one user found the software difficult to 
use. Twenty users were able to run the assay, including an 
approved calibration, without any complications at their 
first attempt, while two users reported having difficulties 
at the first try.
Discussion
This is the most extensive real-life evaluation of ISAC 112 
to date, incorporating a range of varying factors. The per-
formance of the ISAC 112 microarray immunoassay was 
tested at multiple sites worldwide under different labo-
ratory conditions with different operators using microar-
rays from several batches with the aim of maximizing the 
possible sources of variability. The obtained results show 
good consistency in analytical performance across sites, 
and the low frequency of false positive results confirms 
the high specificity of the assay, with a low and stable 
background that was consistent between sites.
The semi-quantitative nature of ISAC means that at 
IgE levels close to the cut-off points, the output is likely 
to fluctuate between concentration categories in different 
assays. However, visualization of discrete data showed 
that assigned categories for a given component were 
consistent between samples and sites, and unsupervised 
clustering showed perfect alignment of samples into 
expected groups, regardless of assay location. Despite the 
semi-quantitative nature of ISAC we have also chosen to 
treat the ISAC results as if they were continuous allowing 
comparison with other reported evaluations of ISAC. Site-
specific means from continuous data (standardized ISU-E) 
were close to the center of the distribution of standardized 
ISU-E values, further indicating that the performance at 
different sites was stable and precise. One European site 
had a mean standardized ISU-E value that was slightly 
higher than the others. When assays were re-run at the 
site, results in better agreement with that of other sites 
were obtained; however, no information was available on 
the cause of the outlying values in the original assays.
A previous version of the ISAC microarray (ISAC 103) 
was reported to show high inter-assay variability for 
certain components [12] that resulted in poor performance 
in detecting sensitizations to certain allergen sources [41]. 
Inter-assay CV of ISAC 103 was > 100%, 33% and 13.2% for 
Low, Medium and High ISU-E categories, respectively [17]; 
however, definitions of the Low and Medium categories 
for ISAC 103 differ from the current definitions for ISAC 
112. These previous estimates of total variation were based 
on within- and between-assay estimates of variability 
obtained using a reproducibility study where all assays 
were run at one site [17]. In the present study the category-
specific estimates of variation ranged from 22 to 27% and 
the overall estimate, CVTotal, was 25.5%. Given the design of 
the current study, which encompassed a wide array of var-
iable factors, the obtained results demonstrate consistent 
performance of the ISAC 112 assay over the entire meas-
urement range. Furthermore, results from this multi-site 
Figure 3: Distribution of standardized ISU values and site means.
Aggregate means of standardized ISU values for the 23 individual sites are indicated by the colored dots.
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study show good coherence with the estimated total CV 
of 17–26.4% from assays performed in one location by a 
single operator using identical instruments and microar-
rays from the same batch (according to the directions for 
use, see Supplemental Data, Table 2).
The results of the present study are also consistent 
with those of other groups. A recent study of the repeat-
ability and reproducibility of ISAC 112, carried out in two 
different laboratories, reported that the reproducibility 
was ‘very good’ for 73 allergens on the microarray and 
‘good’ for 22 allergens according to the classification of 
Fleiss [42] (intra-class correlation coefficients of > 0.90, 
and 0.71–0.90, respectively) [11]. A study of the MeDALL 
custom microarray using a slightly different methodol-
ogy, did not report the overall CV; however, mean CV (all 
concentrations) for the Bet v 1 and Phl p 2 components 
were  ≤  14.1% and  ≤  16.3%, respectively [16].
In conclusion, the outcomes of this study show a very 
robust performance of ISAC 112 across the 23 participating 
sites. Essentially the same results were obtained regard-
less of assay site, laboratory-specific conditions, operator, 
and different batches of the microarray.
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